Eppendorf Award for Young European Investigators opens for entry

Deadline is 15 January 2012

Young researchers working in Europe are invited to apply for the Eppendorf Award for Young European Investigators.

Researchers who are less than 35 have until 15 January 2012 to apply.

The award, inaugurated in 1995, acknowledges outstanding contributions to biomedical research in Europe based on methods of molecular biology, including novel analytical concepts.

An independent expert committee chaired by Kai Simons of the Max Planck Institute for Molecular Cell Biology and Genetics, in Dresden, Germany, will choose the winner.

The successful entrant will receive €15,000 in prize money and an invitation to the prize-giving ceremony at the EMBL Advanced Training Centre in Heidelberg, Germany on 9 May 2012.

In addition, he/she will be invited to Eppendorf in Hamburg and coverage of his/her work will be published in Nature magazine and in a podcast.

The official registration portal is at www.eppendorf.com/award/application. Only online registrations will be accepted.

Full details on the Eppendorf Award, the selection criteria and past award winners, are available at www.eppendorf.com/award.

You may also like

Research & Development

Eppendorf strives to ensure that all labs are smart, safe and stress-free

Eppendorf is a leading life science company that develops and sells instruments, consumables and services for liquid handling, sample handling and cell handling in laboratories worldwide
Manufacturing

Eppendorf launches New Brunswick S41i incubator shaker

Six-sided direct-heating profile provides gentle convection circulation of the chamber
Sustainability

Free online course introduces fundamentals of SFC

Learn how SFC can improve efficiency and reduce environmental impact
Manufacturing

Thermo Fisher launches general purpose centrifuges with natural refrigerant cooling

New X and S Series models offer high performance with reduced environmental impact
Research & Development

€2.5m boost for SensABLATE to revolutionise real-time lung cancer treatment

The next-generation AI and photonics system is designed to provide instant intraoperative confirmation during lung cancer ablation and aims to improve precision, reduce repeat procedures and enhance patient outcomes
Regulatory

FDA grants Medivir’s MIV-711 Orphan Drug Designation for Osteogenesis Imperfecta treatment

The FDA has awarded Orphan Drug Designation to Medivir’s selective cathepsin K inhibitor MIV-711 for Osteogenesis Imperfecta, a rare genetic bone disorder, after preclinical and clinical data suggests the therapy may strengthen bone
Research & Development

Vivan Therapeutics and MRC LMS launch partnership to study how KRAS mutations, diabetes and diet shape cancer drug response

The new collaboration will investigate how KRAS mutations and metabolic conditions such as diabetes influence chemotherapy effectiveness, using high-throughput in vivo “fly avatar” models
Subscribe now